<?xml version="1.0" encoding="UTF-8"?>
<p class="p">For efficient absorption from the GIT, EPL must reach the absorption site in a soluble form; thus, poor solubility is the main factor that retards drug absorption, decreases bioavailability, and may increase the probability of drug damage in the GIT [
 <xref rid="B15-pharmaceutics-11-00040" ref-type="bibr" class="xref">15</xref>]. Improving drug solubility is a major concern of drug formulators, especially for drugs classified as BCS class II drugs in which the dissolution rate represents the rate determining step of the absorption process [
 <xref rid="B16-pharmaceutics-11-00040" ref-type="bibr" class="xref">16</xref>,
 <xref rid="B17-pharmaceutics-11-00040" ref-type="bibr" class="xref">17</xref>]. Several techniques have been studied and used to increase the solubility of lipophilic drugs [
 <xref rid="B16-pharmaceutics-11-00040" ref-type="bibr" class="xref">16</xref>,
 <xref rid="B18-pharmaceutics-11-00040" ref-type="bibr" class="xref">18</xref>].
</p>
